SCHEMBL9290649

SCHEMBL9290649

CCN(CC)CCOc1cc(CNS(=O)(=O)C2CC=CS2)nc(-c2ccccn2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LYN P07948 1/20 0.36
SRC P12931 1/20 0.36
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
APAF1 O14727 1/20 0.34
NSD2 O96028 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CHRNA7 P36544 1/20 0.31
NPY5R Q15761 4/20 0.31
TSHR P16473 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9290569 0.86 LYN (0.39) LYNSRCMAPTKMT2AKDM4E
SCHEMBL9290639 0.86 LYN (0.39) LYNSRCMAPTKMT2AKDM4E
SCHEMBL9290651 0.80 NPY5R (0.44) LYNSRCKMT2AKDM4EMEN1
SCHEMBL9290636 0.80 GPR39 (0.42) KMT2AMEN1L3MBTL1NPY5R
SCHEMBL9290572 0.77 KDM4E (0.43) LYNSRCMAPTKMT2AKDM4E
SCHEMBL9290644 0.77 HPGD (0.42) LYNSRCMAPTKMT2AKDM4E
SCHEMBL8515531 0.73 LYN (0.42) LYNSRCMAPTKMT2AKDM4E
SCHEMBL8514809 0.72 SQLE (0.42) LYNSRCMAPTKMT2AKDM4E
SCHEMBL9290561 0.70 NPY5R (0.45) LMNATP53GAAHTTNPY5R
SCHEMBL9290602 0.69 HTT (0.36) LYNSRCMAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012069428-A1 BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS NOSCIRA, S.A. (ES) 2012-05-31 WO disclosed